4,249 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the second quarter, Holdings Channel.com reports. The firm acquired 4,249 shares of the company’s stock, valued at approximately $716,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of NBIX. Geneos Wealth Management Inc. lifted its position in shares of Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares in the last quarter. DJE Kapital AG purchased a new position in shares of Neurocrine Biosciences in the fourth quarter valued at $28,000. Basecamp Wealth Advisors LLC grew its position in shares of Neurocrine Biosciences by 582.9% in the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after purchasing an additional 204 shares in the last quarter. Cassaday & Co Wealth Management LLC purchased a new position in shares of Neurocrine Biosciences in the first quarter valued at $33,000. Finally, Meeder Asset Management Inc. raised its stake in shares of Neurocrine Biosciences by 651.6% during the 4th quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock valued at $33,000 after purchasing an additional 202 shares during the period. Institutional investors own 92.59% of the company’s stock.

Insiders Place Their Bets

In other Neurocrine Biosciences news, Director Stephen A. Sherwin sold 25,000 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $165.32, for a total value of $4,133,000.00. Following the transaction, the director directly owned 15,860 shares in the company, valued at $2,621,975.20. This represents a 61.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jude Onyia sold 11,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $160.25, for a total value of $1,762,750.00. Following the completion of the sale, the insider directly owned 25,846 shares in the company, valued at approximately $4,141,821.50. The trade was a 29.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 131,524 shares of company stock worth $21,668,924. 4.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

NBIX has been the topic of a number of recent research reports. BMO Capital Markets increased their price objective on Neurocrine Biosciences from $144.00 to $170.00 and gave the stock a “market perform” rating in a report on Monday, July 13th. Stifel Nicolaus lifted their target price on Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a report on Friday, July 31st. Morgan Stanley decreased their price target on Neurocrine Biosciences from $196.00 to $182.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 13th. Cantor Fitzgerald increased their price target on shares of Neurocrine Biosciences from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Finally, The Goldman Sachs Group assumed coverage on shares of Neurocrine Biosciences in a report on Tuesday, June 2nd. They issued a “buy” rating and a $213.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $200.86.

Neurocrine Biosciences Price Performance

NBIX opened at $155.54 on Thursday. The firm has a market capitalization of $15.81 billion, a P/E ratio of 22.81, a price-to-earnings-growth ratio of 0.72 and a beta of 0.39. Neurocrine Biosciences, Inc. has a one year low of $122.14 and a one year high of $186.12. The company has a fifty day moving average price of $167.48 and a 200-day moving average price of $148.73.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Friday, July 31st. The company reported $2.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.65 by $1.20. The company had revenue of $959.00 million for the quarter, compared to the consensus estimate of $891.16 million. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%.The firm’s revenue was up 39.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.65 earnings per share. On average, analysts expect that Neurocrine Biosciences, Inc. will post 7.25 earnings per share for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.